These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 24852755)

  • 1. 3-Deazaneplanocin A (DZNep), an inhibitor of the histone methyltransferase EZH2, induces apoptosis and reduces cell migration in chondrosarcoma cells.
    Girard N; Bazille C; Lhuissier E; Benateau H; Llombart-Bosch A; Boumediene K; Bauge C
    PLoS One; 2014; 9(5):e98176. PubMed ID: 24852755
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Antitumoral Effect of the S-Adenosylhomocysteine Hydrolase Inhibitor, 3-Deazaneplanocin A, is Independent of EZH2 but is Correlated with EGFR Downregulation in Chondrosarcomas.
    Aury-Landas J; Girard N; Lhuissier E; Adouane D; Delépée R; Boumediene K; Baugé C
    Cell Physiol Biochem; 2019; 53(4):731-745. PubMed ID: 31613064
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epigenetic therapy with 3-deazaneplanocin A, an inhibitor of the histone methyltransferase EZH2, inhibits growth of non-small cell lung cancer cells.
    Kikuchi J; Takashina T; Kinoshita I; Kikuchi E; Shimizu Y; Sakakibara-Konishi J; Oizumi S; Marquez VE; Nishimura M; Dosaka-Akita H
    Lung Cancer; 2012 Nov; 78(2):138-43. PubMed ID: 22925699
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A inhibits the growth of cholangiocarcinoma cells.
    Nakagawa S; Sakamoto Y; Okabe H; Hayashi H; Hashimoto D; Yokoyama N; Tokunaga R; Sakamoto K; Kuroki H; Mima K; Beppu T; Baba H
    Oncol Rep; 2014 Feb; 31(2):983-8. PubMed ID: 24337160
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A and the histone deacetylase inhibitor panobinostat against human AML cells.
    Fiskus W; Wang Y; Sreekumar A; Buckley KM; Shi H; Jillella A; Ustun C; Rao R; Fernandez P; Chen J; Balusu R; Koul S; Atadja P; Marquez VE; Bhalla KN
    Blood; 2009 Sep; 114(13):2733-43. PubMed ID: 19638619
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The histone methyltransferase inhibitor, DZNep, up-regulates TXNIP, increases ROS production, and targets leukemia cells in AML.
    Zhou J; Bi C; Cheong LL; Mahara S; Liu SC; Tay KG; Koh TL; Yu Q; Chng WJ
    Blood; 2011 Sep; 118(10):2830-9. PubMed ID: 21734239
    [TBL] [Abstract][Full Text] [Related]  

  • 7. DZNep, inhibitor of S-adenosylhomocysteine hydrolase, down-regulates expression of SETDB1 H3K9me3 HMTase in human lung cancer cells.
    Lee JK; Kim KC
    Biochem Biophys Res Commun; 2013 Sep; 438(4):647-52. PubMed ID: 23933322
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 3-deazaneplanocin A protects against cisplatin-induced renal tubular cell apoptosis and acute kidney injury by restoration of E-cadherin expression.
    Ni J; Hou X; Wang X; Shi Y; Xu L; Zheng X; Liu N; Qiu A; Zhuang S
    Cell Death Dis; 2019 May; 10(5):355. PubMed ID: 31043583
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular mechanisms involved in the synergistic interaction of the EZH2 inhibitor 3-deazaneplanocin A with gemcitabine in pancreatic cancer cells.
    Avan A; Crea F; Paolicchi E; Funel N; Galvani E; Marquez VE; Honeywell RJ; Danesi R; Peters GJ; Giovannetti E
    Mol Cancer Ther; 2012 Aug; 11(8):1735-46. PubMed ID: 22622284
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acquired resistance to DZNep-mediated apoptosis is associated with copy number gains of AHCY in a B-cell lymphoma model.
    Akpa CA; Kleo K; Oker E; Tomaszewski N; Messerschmidt C; López C; Wagener R; Oehl-Huber K; Dettmer K; Schoeler A; Lenze D; Oefner PJ; Beule D; Siebert R; Capper D; Dimitrova L; Hummel M
    BMC Cancer; 2020 May; 20(1):427. PubMed ID: 32408898
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 3-Deazaneplanocin A is a promising therapeutic agent for ovarian cancer cells.
    Shen L; Cui J; Pang YX; Ma YH; Liu PS
    Asian Pac J Cancer Prev; 2013; 14(5):2915-8. PubMed ID: 23803053
    [TBL] [Abstract][Full Text] [Related]  

  • 12. S-Adenosyl-L-methionine-competitive inhibitors of the histone methyltransferase EZH2 induce autophagy and enhance drug sensitivity in cancer cells.
    Liu TP; Lo HL; Wei LS; Hsiao HH; Yang PM
    Anticancer Drugs; 2015 Feb; 26(2):139-47. PubMed ID: 25203626
    [TBL] [Abstract][Full Text] [Related]  

  • 13. DZNep-mediated apoptosis in B-cell lymphoma is independent of the lymphoma type, EZH2 mutation status and MYC, BCL2 or BCL6 translocations.
    Akpa CA; Kleo K; Lenze D; Oker E; Dimitrova L; Hummel M
    PLoS One; 2019; 14(8):e0220681. PubMed ID: 31419226
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Effects of Histone Methyltransferase Inhibitors on the Survival, Apoptosis and Cell Cycle of Raji Cells].
    Xiao LR; Hou C; Zheng SJ; Guo B; Chen DN; Yan NH
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2019 May; 50(3):305-310. PubMed ID: 31631594
    [TBL] [Abstract][Full Text] [Related]  

  • 15. EZH2-Mediated H3K27me3 Is Involved in Epigenetic Repression of Deleted in Liver Cancer 1 in Human Cancers.
    Au SL; Wong CC; Lee JM; Wong CM; Ng IO
    PLoS One; 2013; 8(6):e68226. PubMed ID: 23826380
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of histone methylation arrests ongoing graft-versus-host disease in mice by selectively inducing apoptosis of alloreactive effector T cells.
    He S; Wang J; Kato K; Xie F; Varambally S; Mineishi S; Kuick R; Mochizuki K; Liu Y; Nieves E; Mani RS; Chinnaiyan AM; Marquez VE; Zhang Y
    Blood; 2012 Feb; 119(5):1274-82. PubMed ID: 22117046
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-leukemic effects of HDACi Belinostat and HMTi 3-Deazaneplanocin A on human acute promyelocytic leukemia cells.
    Valiulienė G; Stirblytė I; Jasnauskaitė M; Borutinskaitė V; Navakauskienė R
    Eur J Pharmacol; 2017 Mar; 799():143-153. PubMed ID: 28192098
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genetic or pharmacologic blockade of enhancer of zeste homolog 2 inhibits the progression of peritoneal fibrosis.
    Shi Y; Tao M; Wang Y; Zang X; Ma X; Qiu A; Zhuang S; Liu N
    J Pathol; 2020 Jan; 250(1):79-94. PubMed ID: 31579944
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Superior efficacy of a combined epigenetic therapy against human mantle cell lymphoma cells.
    Fiskus W; Rao R; Balusu R; Ganguly S; Tao J; Sotomayor E; Mudunuru U; Smith JE; Hembruff SL; Atadja P; Marquez VE; Bhalla K
    Clin Cancer Res; 2012 Nov; 18(22):6227-38. PubMed ID: 22932665
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chromatin remodeling by the histone methyltransferase EZH2 drives lung pre-malignancy and is a target for cancer prevention.
    Tellez CS; Picchi MA; Juri D; Do K; Desai DH; Amin SG; Hutt JA; Filipczak PT; Belinsky SA
    Clin Epigenetics; 2021 Feb; 13(1):44. PubMed ID: 33632299
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.